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Introduction: what are mesenchymal stem cells?
Th   e term mesenchymal stem cell (MSC) applies to adult 
ﬁ   broblast-like cells that diﬀ   erentiate along multiple 
mesenchymal pathways when exposed to proper stimuli 
[1,2]. Th  ese cells were identiﬁ  ed  ﬁ   rst in murine bone 
marrow as plastic-adherent cells that formed ﬁ  broblast 
colony-forming units [3]. Other investigators began to 
adapt similar adherent populations as feeder layers for 
the propagation of various hematopoietic cell lineages 
[4]. Th   is usage provided the ﬁ  rst glimpse of the ability of 
MSCs to secrete potent bioactive factors that enabled 
them to regulate the function of other types of cells. Th  is 
cellular regulatory capacity under  lies the current notion 
that MSCs possess thera  peutic potential to promote the 
healing of wounds and ischemic tissues [1,2]. Th  is  implies 
that MSCs can also function as therapeutic cells that 
modulate microenviron  ments and immunological com-
pe  tence, accelerate wound repair, and reduce ﬁ  brosis or 
scar formation or both. A number of recent studies have 
been translating this concept into experimental studies 
and further into clinical applica  tions. To date, such 
applications include cardiovascular disease and myo-
cardial infarction; brain and spinal cord injury; cartilage, 
bone, and tendon repair; Crohn disease; and skin wound 
repair [5-7].
Th   e phenotypic deﬁ  nition of MSCs has been hampered 
by the heterogeneity of this population [8,9]. Hetero-
geneity occurs among cells harvested from a single 
anatomic site and also occurs between cells harvested 
from diﬀ  erent anatomic sites. Bone marrow and adipose 
tissues are currently the major sources for MSCs that are 
being used for preclinical and clinical studies. Adipose 
stromal cells (ASCs), though exhibiting diﬀ  erences, still 
share basic characteristics with bone marrow-derived 
cells [10-12]. As with MSCs, ASCs have been employed 
in animal wound repair models and in preliminary 
clinical studies such as myocardial infarction, Crohn 
disease, and skin wound repair [13]. Cells with MSC 
characteristics have also been identiﬁ  ed in multiple adult 
organs, where these cells are associated with vasculature. 
Th   ese cells include both pericytes in the microvasculature 
and adventitial ﬁ   broblast-like cells that surround the 
larger blood vessels [13-15].
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or other damaged tissues. A current problem is the 
development of strategies that ensure that these cells 
reach wound beds in a timely fashion and in suffi   cient 
numbers to maximize their therapeutic benefi  ts. 
Currently, there are two basic delivery methods: 
systemic infusion of cells into the vascular circulation 
and direct application of therapeutic cells to wound 
sites. Skin wounds are optimal candidates for the 
topical delivery approach. However, the methods by 
which therapeutic cells are delivered to such wounds 
vary. This review outlines the basic methods used to 
deliver therapeutic cells to skin and other wounds. 
Upon entering wounds, therapeutic cells interact with 
other wound cells through paracrine mechanisms that 
are not yet well understood. Nonetheless, interactions 
with vascular endothelial cells and immunomodulation 
appear to play signifi  cant roles in accelerating wound 
healing and in reducing scar formation upon the 
completion of the healing process. Although the 
phenomenological body of evidence indicating the 
effi   cacy of therapeutic cells is substantial, considerable 
work is still required to better determine the molecular 
and cellular functions of these cells and to assess 
their fate and the long-term consequences of their 
application.
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they adhere to tissue culture plastic, express cell surface 
markers for CD105, CD73, and CD90, and fail to express 
cell surface markers for CD45, CD34, CD14, CD11b, 
CD79a, and CD19 [12,16,17]. In addition, these cells are 
negative for class II major histocompatibility markers 
[2,5]. Th  e evolution of therapeutic approaches using 
MSCs has raised new issues regarding the identiﬁ  cation 
of these cells. Th  e abilities to produce paracrine factors 
and to interact with other types of cells typically found in 
wounds require a more extensive investigation to develop 
a functional proﬁ  le for these cells.
Delivery of exogenous mesenchymal stem cells 
to wound/ischemic sites
Most therapeutic applications of MSCs to wound/
ischemic targets dictate that exogenous (for example, 
culture-expanded) populations be delivered using either 
systemic or direct/topical approaches [2,18]. Systemic 
delivery mimics the route of endogenous MSCs via the 
circulatory system with ﬁ   nal homing to target sites. 
During vascular transit, MSCs risk being taken out of 
circulation, on either a temporary or a permanent basis, 
in organs such as the lungs, spleen, and liver [5]. Th  is  may 
either delay their transit or reduce the numbers of cells 
that ﬁ  nally appear at target sites. Upon reaching their 
target site (or sites), MSCs must exit the vasculature to 
enter the connective tissue stromal region where their 
principal functions occur [5].
An alternate method for the delivery MSCs to wound/
ischemic sites is through direct or topical delivery [19]. 
Th  is method is fundamentally diﬀ   erent from systemic 
delivery in that applied MSCs either migrate into the 
wound bed via non-vascular routes or release bioactive 
factors from a bandage or other type of carrier at the 
surface of the wound. A limitation of direct/topical 
delivery is the accessibility of the target site. Skin is an 
example of a highly accessible target site in which large 
surface area wounds and chronic non-healing wounds 
are amenable to topical MSC therapy [19,20]. Topical 
administration of MSCs is generally inapplicable for 
internal organs. However, direct injection of concentrated 
cells has been used to deliver cells to internal organs [9]. 
Nonetheless, this is an invasive procedure with attendant 
risks.
Direct/topical delivery of exogenous mesenchymal 
stem cells
For direct/topical delivery to succeed, a highly concen-
trated population of cells must be either placed onto the 
surface of the wound or injected immediately adjacent to 
the wound. Th   e timing of this administration may also be 
important in that applied MSCs must functionally 
interact with wound cells at critical stages of the healing 
process. Exactly what these interactions are and when 
they occur are currently areas of research interest. Th  e 
importance of delivering a critical number of cells has 
been described by Falanga and colleagues [19]. Th  e 
mechanisms by which MSCs are concentrated at wound 
sites vary among studies. Hanson and colleagues [20] 
have summarized delivery methods that have been 
employed in small-scale clinical studies. Th  ese  methods 
include injection into the wound, inclusion in a topical 
ﬁ   brin spray, and incorporation in a collagen sponge 
[19,21,22]. Similar methods have been employed in 
preclinical studies [19,23,24]. Th  ese studies all report 
improvement in wound healing. However, the variations 
in delivery methods make it diﬃ   cult to critically assess 
cellular and molecular function of MSCs at wound sites. 
Th   e optimal cellular delivery method for a preclinical or 
clinical study will likely depend on the type and location 
of the wound.
Because of its exposed nature, skin has been a target for 
direct/topical delivery in both preclinical and clinical 
studies. Minor skin wounds heal well without treatment; 
however, extensive full-thickness wounds such as those 
that result from polytrauma or burns require intervention 
to heal in a timely manner without excessive scarring 
[25]. Autologous grafts have been used in such situations, 
but there is a limit to the amount of skin available for 
grafting. Autologous and allogeneic skin substitutes have 
also been employed [26]. Th  e integration of MSCs into 
skin substitutes may provide a novel approach in acceler-
ating the healing of these wounds [27]. Chronic non-
healing skin wounds have a deﬁ   cit in vascularity and 
support for vascular function [19,20]. Use of cell-based 
treatments for these wounds is increasing. Th  e  inclusion 
of MSCs into the cellular treatment models for chronic 
wounds has demonstrated promising results [19,20]. 
Cellular therapeutics has multiple aims: to hasten repair, 
to dampen overexuberant inﬂ  ammatory events, and to 
reduce or eliminate scar formation; all of these aims 
require a multifunctional cellular population. In some 
situations, such as for chronic non-healing wounds, the 
objective of cellular therapy is to reverse those cellular 
and vascular events that compromise repair [6,19]. Th  ese 
cells are typically administered in a direct/topical 
manner. As with other cellular-based therapies, the 
cellular and molecular mechanisms by which MSCs exert 
their inﬂ  uences are still under investigation.
Multiple approaches for direct/topical delivery
A critical issue for the direct/topical delivery of 
therapeutic cells is the mechanism by which these cells 
become integrated into the wound. Th  ree examples for 
the delivery of these cells to preclinical skin wounds are 
provided. In each example, therapeutic cells become 
integrated into the wound tissue.
Sorrell and Caplan Stem Cell Research & Therapy 2010, 1:30 
http://stemcellres.com/content/1/4/30
Page 2 of 6Stoﬀ   and colleagues [23] injected concentrated human 
MSCs (hMSCs) into sites immediately adjacent to 
incisional wounds made in the skin of rabbits. Th  ese 
hMSCs migrated from the injection sites and traversed 
the dermal-epidermal junction region of the wound by 
day 14 and had reached the junction between the margin 
of the wound bed and the underlying fascia by day 21. 
Th  ese results provide evidence that MSCs were capable 
of migration through connective tissues and further 
suggested that speciﬁ   c attractive mechanisms were at 
play. Th  e wounds treated with hMSCs regained 52% of 
the normal tensile strength of skin compared with a 31% 
restoration of tensile strength in non-treated wounds. 
Th  is corresponded with a more eﬀ  ective deposition of 
collagenous ﬁ  bers that were also more highly organized. 
In short, scarring was reduced and there was a 
consequent increase in tissue function. Th   e rabbits used 
in the study were fully immunocompetent, and no 
immunosuppressive drugs were given to the animals; 
there was no evidence for the rejection of injected 
xenogenic hMSCs.
Falanga and colleagues [19] approached the problem of 
skin wound repair diﬀ  erently.  Th  ey  incorporated 
autologous MSCs in a ﬁ  brin spray for topical delivery. 
Th  is procedure concentrated the cells and provided a 
non-toxic matrix from which cells could migrate into 
wound beds and was applicable for use for both 
experimental animals and humans. In the experimental 
mouse model, excisional wounds were created on tail 
skin of genetically diabetic (db/db) mice, and ﬁ  brin spay 
was administered with and without autologous MSCs. 
Th  e MSCs were tracked into the wound bed but most 
transited out of the wound by day 21 after application. A 
few isolated cells that remained in the wounds associated 
with vascular structures. Wounds treated with MSCs 
healed signiﬁ  cantly faster and displayed a more mature 
histology than did wounds in which cells were not 
applied. Using autologous MSCs, the authors performed 
a similar study on human chronic non-healing wounds. A 
strong correlation was observed in the number of applied 
cells and the closure of the chronic wounds.
Nambu and colleagues [24] treated excisional wounds 
on db/db mice with autologous ASCs that were incor-
porated in a collagen matrix and found advanced 
granulation tissue formation and re-epithelialization with 
applied cells as compared with controls. Th  ese results 
suggest that ASCs may share similar trophic eﬀ  ects with 
bone marrow-derived MSCs. Another potential method 
for the direct application of MSCs to skin wounds is 
through their incorporation into skin equivalents. Typical 
bilayered skin equivalents consist of an epidermis that 
resides on a ﬁ  broblast-based dermis [28]. Since MSCs are 
a ﬁ  broblastic population, they can be used either alone or 
in combination with dermal ﬁ  broblasts to construct the 
dermal component of skin equivalents [27]. Integration 
of MSCs into a ﬁ   broblast matrix has been shown to 
enhance the angiogenic potential of that matrix [29]. Th  is 
implies that these cells might retain at least some of their 
MSC characteristics. Alternatively, MSCs might acquire a 
more ﬁ  broblast-like phenotype [9].
How do mesenchymal stem cells improve wound 
healing?
Th  e basic mechanisms by which MSCs might improve 
wounds are (a) paracrine communication with resident 
wound cells, inﬁ  ltrating inﬂ  ammatory cells, and antigen-
presenting cells or (b) their diﬀ  erentiation into resident 
cells or (c) both [30,31]. If paracrine activity is their 
primary function in wound repair, their presence in 
wounds would be expected to be transitory. However, if 
they diﬀ  erentiate into structural tissue cells such as ﬁ  bro-
blasts, vascular endothelial cells, or pericytes, their 
presence would be expected to be longstanding. Current 
information on MSC longevity in wounds varies. For 
example, Falanga and colleagues [19] found that most of 
their topically applied MSCs had exited the wound by 25 
days. In contrast, injection of MSCs into the pericardiac 
region revealed the continuous presence of MSCs for up 
to 1 year [32]. Th   ese variations may depend on the type 
of tissue, type of wound, the method of labeling cells, or 
the degree of MSC heterogeneity.
Fate of mesenchymal stem cells delivered 
to wounds
Th   e long-term fate of therapeutic cells in wounds is not 
well characterized. Falanga and colleagues [19] reported 
that nearly all MSCs topically applied to mouse skin 
wounds exited the wounds prior to the completion of 
healing. In contrast, Yamaguichi and colleagues [33] 
found that topically applied MSCs diﬀ   erentiated to a 
myoﬁ  broblast phenotype in rat skin/fascia wounds. Th  e 
diﬀ   erentiation of MSCs into ﬁ   broblasts is normally 
diﬃ   cult to prove since these two types of cells share cell 
surface markers. However, a recent study from Mao and 
colleagues [9] showed that subsets of cloned MSCs are 
capable of acquiring ﬁ   broblast characteristics when 
treated with connective tissue growth factor. Th  ese  cells 
do not express alpha-smooth muscle actin unless they are 
further treated with transforming growth factor-beta-1. 
In most studies, the long-term assessment of MSC fate is 
diﬃ     cult without resorting to non-invasive techniques. 
Wang and colleagues [32] demonstrated that human 
CD34+ MSCs that were injected into a mouse myocardial 
infarct model were retained in the wound region for up 
to 52 weeks. Th  e injected cells were labeled with 
luciferase vector, and a combination of bioluminescence, 
positron emission tomography, and magnetic resonance 
imaging was used to monitor cellular location. Th  ese  cells 
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Assessment of therapeutic cell fate will be important in 
future studies aimed at better understanding the function 
of these cells in wounds.
Paracrine interactions
Paracrine interactions that involve MSCs in a complex 
wound setting require these cells to be capable of produc-
ing and responding to a wide assortment of bioactive 
factors [34,35]. Furthermore, paracrine inter  actions 
imply close cellular juxtapositioning with commu  nicating 
cells, a feature that would require integration of MSCs 
into the wound bed. A detailed understanding of the 
nature of these paracrine interactions will require 
combined  in vivo and in vitro studies. Smith and 
colleagues [36] found that hMSCs in co-culture with 
dermal ﬁ  broblasts inﬂ  uenced the proliferation kinetics, 
migration kinetics, and gene expression proﬁ  les of these 
cells. However, wounds contain multiple subpopulations 
of ﬁ  broblasts that might interact diﬀ  erently than generic 
dermal ﬁ  broblasts [25]. Th  us, the use of wound ﬁ  bro-
blasts in such studies would be more informative. Studies 
have also shown that MSC therapy increases wound-
breaking strength. Th  is entails the production, deposi-
tion, and organization of structural collagens in wounds 
[23,30]. Th  erefore, it will be necessary to better under-
stand how MSCs regulate collagen formation and meta-
bolism in a ﬁ  broblast co-culture setting.
Mesenchymal stem cell interactions with 
vasculature
Th   e interrelationship between MSCs and the vasculature 
is another area of relevance for wound repair. Granulation 
tissue formation is a critical early step in the healing 
process [25]. One of the therapeutic functions of MSCs is 
the early induction of granulation tissue [37-40]. Th  is  is 
followed by the stabilization of the neovascular network 
as wounds begin to heal. A current theory of MSC and 
ASC origin places these cells in perivascular domains in 
their respective organs [41-44]. In addition, analyses of 
newly isolated MSCs and ASCs have shown that these 
cells express markers characteristic of pericytes [44,45]. 
Th  e native pericyte function of these cells may be 
retained in wound tissues. Pericytes are microvascular 
support cells that exhibit phenotypic characteristics 
intermediate between myoﬁ  broblasts and smooth muscle 
cells [40]. Th  ey partially envelop microvascular tubules 
and establish both N-cadherin adherent junctions and 
communicating junctions with microvascular endothelial 
cells of tubules [46]. Th   e neovasculature attracts pericytes 
through the release of the chemokines platelet-derived 
growth factor-BB (PDGF-BB). Th  is interaction could 
explain, at least in part, the motive force behind MSC 
migration into wound tissue. Transforming growth 
factor-beta-1 plays a role in stabilization of pericyte-
endothelial cell complexes, and pericytes release 
angiopoitin-1, which helps to stabilize newly formed 
tubular structures through ligation with the Tie-2 
receptor on endothelial cells [47,48]. Th  us, therapeutic 
functions of MSCs in wounds likely include early 
induction of granulation tissue and stabilization of 
neo vasculature.
Vascular stabilization by MSCs has been demonstrated 
in athymic mice in which mixtures of human umbilical 
vein endothelial cells (HUVECs) and hMSCs were 
implanted either in subcutaneous sites or into the cranial 
cavity [45,49]. As these cells sorted out, HUVECs formed 
vascular structures and MSCs assumed pericyte locations 
and expressed pericyte markers. Th   e MSCs appeared to 
be attracted to the tubules by PDGF-BB [45]. Injection of 
endothelin-1 induced contraction of the human neo-
vasculature, an indication of pericyte function. In long-
term  in vivo studies, vascular tubules retained their 
stability only when MSCs were present. In vitro co-
culture studies have also shown that MSCs increase 
tubule formation by HUVECs and that these MSCs 
assume pericyte-like positions on the tubules that these 
endothelial cells formed [29]. Taken together, these 
studies suggest that major therapeutic functions of MSCs 
and ASCs are to induce early granulation tissue formation 
and to stabilize neovasculature at wound sites.
Mesenchymal stem cell modulation of immune 
and rejection responses
MSC cellular interactions transcend the interactions with 
vascular endothelial cells, and the potent immuno  modu-
latory activities of MSCs augment other repair functions 
through multifold, complex steps. Th  e  ﬁ  rst step in MSC 
immunomodulation requires the activation of these cells 
with interferon-gamma, which is presented in combi-
nation with other factors such as tumor necrosis factor-
alpha or interleukin-1 [50]. Th   is activation results in the 
upregulated release of soluble factors such as indole-
amine 2,3-dioxygenase, inter  leukin-10, and prosta  glandin 
E2. In proper combinations, factors released by stimulated 
MSCs suppress the mitogen-induced prolif  era  tion of 
both CD4+ and CD8+ T cells [51]. Th   ese factors may also 
promote the generation of immunoregulatory T cells and 
functionally interact with natural killer cells and 
immature dendritic cells [50]. Th  ese activities have 
therapeutic potentials, some of which have already been 
documented in preclinical and clinical studies [2,5,7,52].
MSC/ASC introduction into wound/ischemic sites via 
the direct/topical approach also raises issues of whether 
these cells can exert similar immunomodulatory skills. 
For example, these cells may increase tolerance for the 
engraftment of skin equivalents constructed from 
allogeneic cells and help to promote vascular ingrowth 
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the reduction of scar formation. Dendritic cells and a 
specialized ﬁ  brocyte population that migrates to wounds 
appear to play roles in hypertrophic scar formation [54]. 
Th   e presence of MSCs/ASCs may dampen the eﬀ  ects of 
these cells, thus reducing scarring. As reported above, 
Stoﬀ    and colleagues [23] found that xenogenic MSCs 
increased the tensile strength of healed incisional 
wounds. Apparently, this resulted from the more eﬀ  ective 
organization of newly produced collagenous ﬁ  bers at the 
wound site. Th  us, MSCs may also play a role in the 
regulation of matrix deposition and organization, which 
are important late-stage steps during wound repair [25]. 
In adults, wound repair is associated with atypical matrix 
deposition that may be related to the overproduction of 
factors such as transforming growth factor-beta-1 [55]. 
Modulation of growth factor expression at wound sites 
could regulate scar formation. Th  us, MSCs may act at 
multiple stages of wound repair, but with diﬀ  erent 
functions. Th   e mechanism of delivery may not be critical 
in this regard.
Th   e immunomodulatory functions of MSCs are 
important for clinical applications of these cells. First, 
these functions facilitate the application of allogeneic 
cells to wounds, thus creating the potential for oﬀ  -the-
shelf products. Second, these functions may dampen 
over exuberant  inﬂ   ammatory responses that retard 
wound healing. Finally, they reduce scar formation 
through interactions with dendritic cells and ﬁ  brocytes 
that are associated with scar formation.
Summary, conclusions, and clinical relevance
A substantial body of current evidence supports the 
notion that MSCs and ASCs serve as therapeutic cells in 
wound/ischemic situations. Unfortunately, most of the 
existing studies are phenomenological. Th  is means that 
there is still a considerable body of work required to 
address basic issues: What is the most eﬀ  ective means of 
delivering therapeutic cells to target sites? What are the 
cellular and molecular functions of these cells at their 
target sites? What is the ultimate fate of these cells upon 
the successful healing of the wound? Answers to these 
basic questions will engender improved approaches for 
cellular therapeutics. Th  e timing of therapeutic cell 
delivery may be critical. Topical delivery provides a 
means to better regulate this aspect of their application. 
Cellular populations within wounds change depending 
on the phases of the repair process [25]. Th   is means that 
therapeutic cells will encounter diﬀ  erent microenviron-
ments at each stage of the repair process. Th  us,  develop-
ing an understanding of both when and how to best 
deliver these cells to wound sites will be critical for 
maximizing their potential. Issues regarding the long-
term safety of cellular therapy and whether oﬀ  -the-shelf 
products can be eﬀ  ectively developed will also determine 
the future of this approach.
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